<DOC>
	<DOCNO>NCT00557531</DOCNO>
	<brief_summary>This Phase I , multi-center , open label study design ass safety feasibility injectable BL-1040 implant provide scaffold infarcted myocardial tissue .</brief_summary>
	<brief_title>Safety Feasibility Injectable BL-1040 Implant</brief_title>
	<detailed_description>ENDPOINTS Preliminary safety endpoint Occurrence adverse event include limit All MIs Cardiovascular hospitalization Serious ventricular arrhythmia sustain : VT ( symptomatic sustain VT [ duration longer 30 second 100 beat , associate hemodynamic collapse ] ) VF symptomatic bradycardia , pause long 3.0 second , complete atrioventricular block , Mobitz II atrioventricular block Symptomatic heart failure ( NYHA criterion + physical examination OR hospitalization due heart failure ) Renal failure Stroke Death Secondary safety endpoint Change baseline LV dimension ( end-systolic volume index , end-diastolic volume index ) Change baseline regional ( infarct relate ) global wall motion score Change baseline ejection fraction Cardiac rupture NT-proBNP</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<criteria>Signed informed consent 18 75 year age , inclusive Male female Negative pregnancy test woman childbearing potential , surgically sterile , post menopausal Acute MI define : Typical rise gradual fall ( troponin ) rapid rise fall ( CKMB ) biochemical marker myocardial necrosis least one following : Ischemic symptom ; Development pathologic Qwaves ECG ; ECG change indicative ischemia ( ST segment elevation depression ) First anterior inferolateral STEMI Qwave MI ( QMI Anterior : V1V3 V1V4 V1V5 V1V6.QMI Inferior : L2 , L3 , AVF , L2 , L3 , AVF+ V5 , V6 L2 , L3 , AVF+ V6V9 [ posterior lead ] ) Regional wall motion score index ( least 4 16 akinetic segment ) One following : LVEF &gt; 20 % &lt; 45 % measure calculate 2dimensional measurement Biomarkers : peak CK &gt; 2000 IU Infarct size &gt; 25 % measure MRI Successful revascularization PCI 1 stent , within 7 day index MI At time application study device , patient must patent infarct relate artery ( IRA ) TIMI flow grade = 3 History CHF , Class I Class IV , per NYHA criterion History prior LV dysfunction At time application study device Killip IIIIV ( pulmonary edema , cardiogenic shock hypotension systolic &lt; 90 mmHg evidence peripheral hypoperfusion oliguria , cyanosis , sweat ) HR &gt; 100 bpm Prior CABG Prior MI History stroke Significant valvular disease ( moderate severe ) Patient candidate CABG PCI nonIRA Patient consider CRT within next 30 day Renal insufficiency ( eGFR &lt; 60 ) Chronic liver disease ( &gt; 3 time upper limit normal ) Life expectancy &lt; 12 month Current participant another clinical trial , participation another trial within last 6 month Any contraindication coronary angiography , MRI PCI procedures Patient take anticoagulation medication prior MI Pregnant lactate woman ; pregnancy confirm urine pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>